EP1143993A4 - Method of suppressing ongoing acute allograff rejection - Google Patents

Method of suppressing ongoing acute allograff rejection

Info

Publication number
EP1143993A4
EP1143993A4 EP00903388A EP00903388A EP1143993A4 EP 1143993 A4 EP1143993 A4 EP 1143993A4 EP 00903388 A EP00903388 A EP 00903388A EP 00903388 A EP00903388 A EP 00903388A EP 1143993 A4 EP1143993 A4 EP 1143993A4
Authority
EP
European Patent Office
Prior art keywords
allograff
rejection
ongoing acute
suppressing ongoing
suppressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00903388A
Other languages
German (de)
French (fr)
Other versions
EP1143993A1 (en
Inventor
Masakazu Kobayashi
Hongsi Jiang
Xiu-Fen Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of EP1143993A1 publication Critical patent/EP1143993A1/en
Publication of EP1143993A4 publication Critical patent/EP1143993A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP00903388A 1999-01-22 2000-01-21 Method of suppressing ongoing acute allograff rejection Withdrawn EP1143993A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11684599P 1999-01-22 1999-01-22
US116845P 1999-01-22
PCT/US2000/001553 WO2000043030A1 (en) 1999-01-22 2000-01-21 Method of suppressing ongoing acute allograff rejection

Publications (2)

Publication Number Publication Date
EP1143993A1 EP1143993A1 (en) 2001-10-17
EP1143993A4 true EP1143993A4 (en) 2004-11-17

Family

ID=22369594

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00903388A Withdrawn EP1143993A4 (en) 1999-01-22 2000-01-21 Method of suppressing ongoing acute allograff rejection

Country Status (3)

Country Link
EP (1) EP1143993A4 (en)
JP (1) JP2002535283A (en)
WO (1) WO2000043030A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553932B1 (en) 2005-04-25 2009-06-30 La Jolla Institute For Allergy And Immunology Methods of treating viral infection with IL-10 receptor antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562853A1 (en) * 1992-03-27 1993-09-29 American Home Products Corporation 29-Demethoxyrapamycin for inducing immunosuppression

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031532A1 (en) * 1996-02-28 1997-09-04 University Of Medicine & Dentistry Of New Jersey Antisense interleukin 10 and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562853A1 (en) * 1992-03-27 1993-09-29 American Home Products Corporation 29-Demethoxyrapamycin for inducing immunosuppression

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FUJIMURA T ET AL: "Cellular surface molecular and cytokine gene expression in rat heart allografts under optimal doses of cyclosporine and FK 506", TRANSPLANTATION PROCEEDINGS, vol. 30, no. 4, June 1998 (1998-06-01), & PROCEEDINGS OF AN INTERNATIONAL CONGRESS ON IMMUNOSUPPRESSION; ORLANDO, FLORIDA, USA; DECEMBER 11-13, 1997, pages 1023 - 1026, XP001183257, ISSN: 0041-1345 *
JIANG H ET AL: "Inhibition of IL-10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat.", TRANSPLANTATION PROCEEDINGS. 1999 FEB-MAR, vol. 31, no. 1-2, February 1999 (1999-02-01), pages 1203 - 1205, XP001183259, ISSN: 0041-1345 *
LI WEI ET AL: "Systemic administration of anti-interleukin-10 antibody prolongs organ allograft survival in normal and presensitized recipients", TRANSPLANTATION (BALTIMORE), vol. 66, no. 12, 27 December 1998 (1998-12-27), pages 1587 - 1596, XP009036499, ISSN: 0041-1337 *
PLATZ KLAUS-PETER ET AL: "Cytokine pattern during rejection and infection after liver transplantation-improvements in postoperative monitoring?", TRANSPLANTATION (BALTIMORE), vol. 62, no. 10, 1996, pages 1441 - 1450, XP009036500, ISSN: 0041-1337 *
See also references of WO0043030A1 *
SUTHANTHIRAN M: "Clinical application of molecular biology: A study of allograft rejection with polymerase chain reaction", AMERICAN JOURNAL OF MEDICAL SCIENCES, XX, XX, vol. 313, no. 5, May 1997 (1997-05-01), pages 264 - 267, XP008026444, ISSN: 0002-9629 *
ZIPPERLE S ET AL: "Impaired T-cell IL-10 secretion and CD4 helper function in liver transplant patients treated with tacrolimus", TRANSPLANTATION PROCEEDINGS, vol. 29, no. 1-2, 1997, & SIXTEENTH INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY; BARCELONA, SPAIN; AUGUST 25-30, 1996, pages 1079 - 1080, XP001183261, ISSN: 0041-1345 *

Also Published As

Publication number Publication date
WO2000043030A1 (en) 2000-07-27
JP2002535283A (en) 2002-10-22
EP1143993A1 (en) 2001-10-17

Similar Documents

Publication Publication Date Title
GB2351661B (en) Novel method of treatment
IL145875A0 (en) Novel method of treatment
GB2363041B (en) Method of processing frames
PL342076A1 (en) Method of treating surfaces
GB2349190B (en) Method of manufacturing common rails
GB2389182B (en) Method of purifying b-secretase
EP1143993A4 (en) Method of suppressing ongoing acute allograff rejection
PL341752A1 (en) Method of obtaining aryloamino hydroxyantraquinones
GB9930688D0 (en) Novel method of treatment
IL129327A0 (en) Method of preventing allograft rejection
IL128731A0 (en) Method of preventing allograft rejection
GB9924752D0 (en) Method of construction
GB9812941D0 (en) Method of treatment
EP1135128A4 (en) Novel method of treatment
PL333334A1 (en) Method of obtaining silylethenes
PL336600A1 (en) Method of making filtering half-masks
PL336550A1 (en) Method of decoposing 2-chloroethenylchloroarsazine
GB9930696D0 (en) Novel method of treatment
GB9822681D0 (en) Method of treatment
GB9901093D0 (en) Method of making coatings
PL335627A1 (en) Method of obtaining 8beta-hydroxyandrostendione
PL333032A1 (en) Method of obtaining nalpha-benzyloxycarbonyl-l-lysine
PL333385A1 (en) Method of obtaining bisphenoles
PL335392A1 (en) Method of obtaining 4-hydroxy-beta-ionone
PL335626A1 (en) Method of obtaining 8beta-hydroxy-19-norandrostendione

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010725

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YANG, XIU-FEN

Inventor name: KOBAYASHI, MASAKAZU

Inventor name: JIANG, HONGSI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 49/00 B

Ipc: 7A 61K 48/00 B

Ipc: 7A 61K 39/395 B

Ipc: 7A 61P 37/06 B

Ipc: 7A 61K 38/13 A

Ipc: 7A 61K 31/436 B

A4 Supplementary search report drawn up and despatched

Effective date: 20040930

17Q First examination report despatched

Effective date: 20050512

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ASTELLAS PHARMA INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061228